Abcellera Biologics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 15, 2021, reports on the results of Abcellera Biologics Inc.'s Annual Meeting of Shareholders held on that date. The Company is an emerging growth company incorporated in British Columbia with common shares (ABCL) traded on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance matters.
Material Changes and Voting Results
Shareholders voted on two proposals as of the record date of April 19, 2021, when 270,925,888 common shares were outstanding. Both proposals were approved:
- Proposal 1 (Director Election): Shareholders elected Véronique Lecault and John Edward Hamer as Class I directors for a three-year term.
- Proposal 2 (Auditor Ratification): Shareholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
Voting Breakdown
| Nominee / Proposal | For | Against | Abstain |
|---|---|---|---|
| Véronique Lecault | 157,974,274 | 10,311,986 | 1,087,724 |
| John Edward Hamer | 156,787,159 | 11,335,006 | 1,251,819 |
| Ratify KPMG LLP (Proposal 2) | 181,726,536 | 62,376 | 42,162 |
Broker non-votes for Proposal 1 totaled 12,457,090 common shares.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a procedural report regarding shareholder voting outcomes.
Key Facts for Investor Verification
- Confirmation that Véronique Lecault and John Edward Hamer have assumed their roles as Class I directors.
- Verification that KPMG LLP is the appointed auditor for the 2021 fiscal year.
- Review of the Definitive Proxy Statement filed on April 28, 2021, for detailed background on the nominees and proposals.